انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Episode 905: Oseltamivir (Tamiflu) for Influenza
Manage episode 420532993 series 2942787
Contributor: Aaron Lessem MD
Educational Pearls:
Oseltamivir (Tamiflu) is an antiviral medication used commonly to treat influenza
Trials show that the medication reduces the duration of illness by less than 1 day (~16 hours in one systematic review)
Benefit only occurs if taken within 48 hours of symptom onset
Must be taken for 5 days
A 2024 meta-analysis reviewed 15 randomized-controlled trials for the risk of hospitalization
No reduction in hospitalizations with oseltamivir in patients over the age of 12
No difference in high-risk patients over the age of 65 or those with comorbidities
The authors note that the confidence interval in these populations is wide, indicating a need for subsequent studies in high-risk populations
Oseltamivir is associated with adverse effects including nausea, vomiting, and neurologic symptoms
The risk of adverse effects may outweigh the benefits of a small reduction in the duration of illness
References
1. Hanula R, Bortolussi-Courval É, Mendel A, Ward BJ, Lee TC, McDonald EG. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients with Influenza: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024;184(1):18-27. doi:10.1001/jamainternmed.2023.0699
2. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(April):1-18. doi:10.1136/bmj.g2545
Summarized by Jorge Chalit, OMSII | Edited by Meg Joyce & Jorge Chalit
1064 حلقات
Manage episode 420532993 series 2942787
Contributor: Aaron Lessem MD
Educational Pearls:
Oseltamivir (Tamiflu) is an antiviral medication used commonly to treat influenza
Trials show that the medication reduces the duration of illness by less than 1 day (~16 hours in one systematic review)
Benefit only occurs if taken within 48 hours of symptom onset
Must be taken for 5 days
A 2024 meta-analysis reviewed 15 randomized-controlled trials for the risk of hospitalization
No reduction in hospitalizations with oseltamivir in patients over the age of 12
No difference in high-risk patients over the age of 65 or those with comorbidities
The authors note that the confidence interval in these populations is wide, indicating a need for subsequent studies in high-risk populations
Oseltamivir is associated with adverse effects including nausea, vomiting, and neurologic symptoms
The risk of adverse effects may outweigh the benefits of a small reduction in the duration of illness
References
1. Hanula R, Bortolussi-Courval É, Mendel A, Ward BJ, Lee TC, McDonald EG. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients with Influenza: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024;184(1):18-27. doi:10.1001/jamainternmed.2023.0699
2. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(April):1-18. doi:10.1136/bmj.g2545
Summarized by Jorge Chalit, OMSII | Edited by Meg Joyce & Jorge Chalit
1064 حلقات
Kaikki jaksot
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.